Citalopram, a selective serotonin reuptake inhibitor (SSRI), inhibits platelet function in vitro. We have previously shown that this action is independent of citalopram's ability to block serotonin uptake by the serotonin transporter and must therefore be mediated via distinct pharmacological mechanisms. We now report evidence for two novel and putative mechanisms of citalopram-induced platelet inhibition. Firstly, in platelets, citalopram blocked U46619-induced Rap1 activation and subsequent platelet aggregation, but failed to inhibit U46619-induced increases in cytosolic Ca 2+ . Similarly, in neutrophils, citalopram inhibited Rap1 activation and downstream functions but failed to block PAF-induced Ca 2+ mobilisation. In a cell-free system, citalopram also reduced CalDAG-GEFI-mediated nucleotide exchange on Rap1B. Secondly, the binding of anti-GPVI antibodies to resting platelets was inhibited by citalopram. Furthermore, citalopram-induced inhibition of GPVI-mediated platelet aggregation was instantaneous, reversible and displayed competitive characteristics, suggesting that these effects were not caused by a reduction in GPVI surface expression, but by simple competitive binding. In conclusion, we propose two novel, putative and distinct inhibitory mechanisms of action for citalopram: (1) inhibition of CalDAG-GEFI/Rap1 signalling, and (2) competitive antagonism of GPVI in platelets. These findings may aid in the development of novel inhibitors of CalDAG-GEFI/Rap1-dependent nucleotide exchange and novel GPVI antagonists.
Citalopram, a selective serotonin reuptake inhibitor (SSRI), is widely used as an antidepressant 1 . Its primary pharmacological target is the serotonin transporter (SERT) 2, 3 inhibition of which prevents cellular uptake of serotonin (5-hydroxytryptamine, 5-HT) 4 . SSRIs are widely believed to exert psychiatric benefit by inhibiting SERT and modifying serotonergic neurotransmission in the central nervous system 5 . SERT is also found on non-neuronal cells, including platelets, which store 5-HT in dense granules that resemble neurotransmitter vesicles 6, 7 . Citalopram not only inhibits platelet SERT, but also platelet aggregation, adhesion, thromboxane A 2 (TxA 2 ) synthesis and dense granule release [8] [9] [10] [11] [12] . However, this functional inhibition is not caused by blockade of 5-HT uptake and must therefore be mediated by distinct pharmacological mechanisms of action 10 . Citalopram inhibits platelet aggregation induced by both collagen and the TxA 2 mimetic, U46619, countering the claim that it is a specific inhibitor of collagen-induced platelet activation 9 . Nevertheless, citalopram is a more potent inhibitor of collagen 10 , which activates platelets predominantly via glycoprotein VI (GPVI), than U46619, a thromboxane prostanoid (TP) receptor agonist, suggesting differential mechanisms of action. Reduced phosphorylation of signalling proteins in the GPVI pathway 10 points to GPVI as a possible site of action for citalopram, which could act as a classical competitive antagonist or allosteric inhibitor. For example, citalopram could disrupt GPVI dimers that mediate collagen binding and platelet activation 13 . However, GPVI inhibition would not account for citalopram's effect on U46619-induced responses.
Both GPVI and TP receptor activation raise cytosolic calcium concentrations ([Ca 2+ ] cyt ), a shared signalling pathway for collagen, TxA 2 , and many other platelet agonists. Although there are numerous reports of citalopram inhibiting platelet aggregation in vitro [8] [9] [10] [11] [12] few have directly measured its effect on Ca 2+ signalling. Tseng et al. 14 to the small GTPase Rap1, a process catalysed by the calcium and diacylglycerol guanine nucleotide exchange factor-1 (CalDAG-GEFI, also known as RAS guanyl-releasing protein 2) [15] [16] [17] . Rap1-GTP mediates the transition of integrin α IIb β 3 (also known as glycoprotein (GP) IIb/IIIa) to a high-affinity state, thereby facilitating platelet aggregation through fibrinogen crosslinks 18, 19 . Therefore, our search for novel mechanisms for citalopram focussed on GPVI and Ca 2+ signalling. We utilised the selective GPVI agonist, collagen-related peptide (CRP), and also investigated Ca 2+ signalling in neutrophils, which share similar Ca 2+ -dependent mechanisms of activation 20, 21 and are also inhibited by SSRIs in vitro 22 . Our data reveal two novel, putative inhibitory mechanisms of action for citalopram.
Results

MECHANISM 1: Inhibition of CalDAG-GEFI-dependent Rap1 nucleotide exchange. Differential inhibition of GPVI-dependent and U46619-induced calcium mobilisation.
Citalopram inhibits both collagenand U46619-induced platelet aggregation 10 . Since aggregation is dependent on Ca 2+ signalling, the effect of citalopram on agonist-induced increases in [Ca 2+ ] cyt was investigated. Cross-linked CRP (CRPXL), a selective agonist for GPVI, was used instead of collagen to generate exclusively GPVI-dependent responses. [Ca 2+ ] cyt was monitored in platelets pre-treated for approximately 5 min with citalopram (0, 10, 20, 50, 100 & 200 µM), before stimulation with either CRPXL (0.5 µg mL −1 ) or U46619 (0.2 µM). These just sub-maximal concentrations of CRPXL and U46619 were selected based on prior pilot experiments ( Supplementary Fig. S1 ).
CRPXL-induced increases in [Ca 2+ ] cyt were abolished by citalopram (Fig. 1a,b) . The inhibitory potency of citalopram (pIC 50 = 4.34 ± 0.09 (N = 7 blood donors)) matched its potency for inhibiting collagen-induced aggregation (pIC 50 = 4.31 ± 0.21 10 ). This is also consistent with our previous observations that citalopram inhibited tyrosine phosphorylation signalling downstream of GPVI 10 . Surprisingly, and in stark contrast, citalopram had no discernible effect on U46619-induced increases in [Ca 2+ ] cyt (Fig. 1c,d ) (N = 7 blood donors). To confirm that Fura-2-loading had no functional effect on platelets, on one occasion, U46619-induced aggregation was measured in the same preparation of Fura-2-loaded platelets used for Ca 2+ measurements. Fura-2-loaded platelets aggregated normally in response to 0.2 µM U46619 (Fig. 1e ) and citalopram (200 µM) inhibited this response, as expected. However, as reported above, the increase in [Ca 2+ ] cyt was unaffected by citalopram. Thus, in citalopram-treated platelets, U46619 induced a normal Ca 2+ response, but no aggregation, suggesting that citalopram inhibits aggregation at a point downstream of Ca 2+ mobilisation. This conclusion was supported by the observation that citalopram also inhibited platelet aggregation induced by the Ca 2+ ionophore, ionomycin (0.5 µM), in a concentration-dependent manner: pIC 50 = 3.98 ± 0.09 (N = 4 blood donors) ( Supplementary  Fig. S2 ).
Citalopram inhibits Rap1 activation in platelets. U46619-induced platelet activation was inhibited by citalopram, despite preserved Ca 2+ store release (Fig. 1) . We therefore aimed to identify where citalopram exerts its inhibitory effects downstream of Ca 2+ release. Increased [Ca 2+ ] cyt causes CalDAG-GEFI-mediated Rap1 activation and downstream platelet aggregation 15, 17 . Experiments were conducted to determine if citalopram inhibits U46619-induced platelet aggregation by preventing Rap1 activation. The effect of citalopram (200 µM) on Rap1 activation induced by CRPXL (0.5 µg mL −1 ) or U46619 (0.2 µM) was investigated. Activated Rap1 (Rap1-GTP) was isolated and quantified by Western blot analysis. The results (Fig. 2a) clearly show that citalopram inhibited both CRPXL-and U46619-induced Rap1-GTP formation (P = 7.5 × 10
, F = 83.4, as determined by regression analysis (Supplementary Analysis 1) ). Thus, Rap1 activation is blocked by concentrations of citalopram that inhibit U46619-induced platelet aggregation, but have no effect on Ca 2+ release from intracellular stores. Further experiments were conducted to investigate whether citalopram suppresses CalDAG-GEFI-mediated nucleotide exchange of isolated Rap1, using purified recombinant CalDAG-GEFI and Rap1B, the predominant Rap1 isotype in platelets 17, 23 . Nucleotide exchange was monitored by detecting fluorescent BODIPY-FL-conjugated GDP as described in the Methods. Citalopram inhibited CalDAG-GEFI-mediated BODIPY-FL-GDP exchange onto Rap1B in a concentration-dependent manner (Fig. 2b,c) . Peak increases in fluorescence intensity (ΔF.I.) were fitted to the four-parameter logistic (4PL) model, with the Max parameter constrained to the basal response, indicated by the ΔF.I. observed when no CalDAG-GEFI was added. The pIC 50 value was 3.67 ± 0.32 (N = 4 experiments).
Citalopram inhibits Rap1 activation in neutrophils.
The results above indicate that citalopram inhibits CalDAG-GEFI-dependent Rap1B nucleotide exchange and imply that other cells expressing CalDAG-GEFI/Rap1 would also be inhibited by citalopram. Similarly to platelets, neutrophils express both CalDAG-GEFI and Rap1 (the predominant form is also Rap1B 24 ), which mediate agonist and Ca 2+ -dependent activation 21, 25 . Signalling and functional studies were therefore conducted on isolated neutrophils to determine the effects of citalopram treatment.
Platelet-activating factor (PAF) is a potent activator of neutrophils. PAF-induced (1 µM) increases in the [Ca 2+ ] cyt were measured following a 5 min citalopram pre-treatment (0, 10, 20, 50, 100, 200 & 500 µM). As with platelets, citalopram did not affect PAF-induced increases in [Ca 2+ ] cyt in neutrophils (N = 6 blood donors) (Fig. 3a,b) , whereas PAF-induced (1 µM) Rap1 activation was inhibited by citalopram (200 µM) (Fig. 3c) .
, F = 38.7, as determined by regression analysis (Supplementary Analysis 2) ).
Citalopram inhibits neutrophil function. Rap1 regulates the transition of α M β 2 integrin (Mac-1, CD11b/18) to a high-affinity binding state in macrophages 26 . α M β 2 is a cell surface adhesion receptor for fibrinogen 27 and CalDAG-GEFI-deficient neutrophils stimulated with PAF show impaired α M β 2 -dependent adhesion to fibrinogen The membrane integrity of neutrophils was also assessed to check if impaired functional responses in the presence of citalopram were a result of cell cytotoxicity. Citalopram (0, 10, 20, 50, 100, 200 & 500 µM) had no effect on lactate dehydrogenase (LDH) release ( Supplementary Fig. S3 : N = 5 blood donors).
Inhibition of neutrophil signalling and function by citalopram closely matched that observed in platelets. Therefore, these data support the hypothesis that citalopram inhibits CalDAG-GEFI-dependent Rap1 nucleotide exchange.
MECHANISM 2: GPVI antagonism. Inhibition of CRPXL-induced Ca
2+ signalling by citalopram (Fig. 1a,b) is consistent with our previous observations that GPVI-mediated tyrosine phosphorylation of PLCγ2 is inhibited by citalopram 10 . It also suggests that citalopram has a mechanism of action distinct from the inhibition of CalDAG-GEFI-dependent Rap1 nucleotide exchange. Given that citalopram also reduces phosphorylation of FcRγ chain and Src family kinases (SFKs) 10 we hypothesised that citalopram may have a direct effect on GPVI structure and/or function. Citalopram inhibits the binding of GPVI antibodies. GPVI is expressed on the surface of platelets in both monomeric and dimeric conformations, although the dimeric form is thought to be particularly important in collagen binding and subsequent platelet activation 13, 28 . We hypothesised that citalopram may disrupt the dimeric structure of GPVI, thereby preventing collagen-and CRPXL-induced responses. Experiments were conducted using antibodies that selectively detect either dimeric GPVI (204-11 Fab fragments) or total (dimeric and monomeric) GPVI (HY-101) to determine whether citalopram altered GPVI-dimer expression.
Citalopram reduced the fluorescence intensity (F.I.) of unstimulated platelets labelled with 204-11 Fab fragments and HY-101 antibodies in a concentration-dependent manner (Fig. 4) . M.F.I. from platelet samples were fitted to the 4PL model, with the Max parameter constrained to the F.I. of the isotype control (Fig. 4b,d : pIC 50 (204-11) = 4.16 ± 0.03; pIC 50 (HY-101) = 3.93 ± 0.07 (N = 6 blood donors)). These data suggest that citalopram either reduces total GPVI surface expression or blocks the binding of GPVI antibodies to GPVI. The reduction in HY-101 antibody binding suggests that the effect of citalopram is not specific to dimeric GPVI.
Citalopram-induced inhibition of GPVI-mediated platelet activation is fully reversible.
We next investigated whether the impaired GPVI antibody binding caused by citalopram was due to a functionally irreversible mechanism of action such as receptor shedding or internalisation. Platelets were pre-incubated for approximately 5 min with citalopram (0 & 100 µM), which was subsequently removed by pelleting and resuspending platelets in fresh calcium-free Tyrode's (CFT) containing no citalopram (Fig. 5a ). Platelets were then stimulated with CRPXL, with or without citalopram, under standard aggregometry conditions. As expected, citalopram (100 µM) inhibited CRPXL-induced platelet aggregation (Fig. 5c,d ). Resuspension of citalopram-treated platelets in fresh CFT restored CRPXL-induced aggregation and the resuspended control and Citalopram rapidly inhibits CRPXL-induced platelet aggregation in a competitive manner. As shown above, citalopram inhibited the binding of anti-GPVI antibodies and platelet stimulation by CRPXL. However, this latter effect was fully reversible, suggesting that citalopram may bind reversibly to GPVI, thereby preventing binding of the anti-GPVI antibodies and CRP. Such a mechanism would be rapid in onset and competitive in character. We therefore performed additional experiments to investigate the kinetics of onset of platelet inhibition by citalopram, and whether it exhibited a competitive or non-competitive pattern of inhibition.
CRPXL-induced (1 µg mL −1 ) platelet aggregation was completely inhibited by citalopram (100 µM) following either short pre-incubation times (30, 60 seconds) or on simultaneous addition with CRPXL (i.e., 0 seconds pre-incubation) (Fig. 6a,b) . The same result was observed with collagen as an agonist ( Supplementary  Fig. S6 ). Following 5 min pre-incubations, citalopram inhibited CRPXL-induced platelet aggregation in a concentration-dependent manner (Fig. 6c,d ). Pre-incubating platelets with 20 µM and 50 µM citalopram caused 2.1-fold and 5.3-fold rightward shifts in agonist-response curves, respectively (Fig. 6d) . Schild analysis (Fig. 6d) . Inclusion of this concentration into the Schild analysis increased the Schild slope to 1.60 ± 0.05 (Fig. 6e) . In three experiments, at 200 µM citalopram, there was no response to CRPXL (highest concentration tested = 20 µg mL −1 ). These data suggest that at concentrations up to approximately 50 µM, citalopram inhibits CRPXL-induced platelet aggregation in a manner consistent with a competitive mechanism of action. Above this concentration, this pattern breaks down as may be predicted since, at these higher concentrations, citalopram will also exert inhibitory effects via its action on CalDAG-GEFI/Rap1. 
Discussion
We have previously shown that citalopram-induced inhibition of platelet function is not caused by blockade of SERT-dependent 5-HT uptake into platelets 10 . The aim of this study was to identify putative SERT-independent mechanisms of platelet inhibition by citalopram. Specifically, we have characterised the effects of citalopram on two distinct processes: (1) Rap1 activation and (2) GPVI receptor function.
In platelets and neutrophils, activation of both TP and PAF receptors respectively induces Ca 2+ release from intracellular stores via G protein-mediated activation of phospholipase Cβ (PLCβ) [29] [30] [31] . In both cell types, citalopram failed to inhibit either U46619-or PAF-induced Ca 2+ release indicating that the signalling pathways from receptor to elevated [Ca 2+ ] cyt were unaffected by the drug. By contrast, citalopram did block downstream Rap1 activation and cell function. Similarly, Tseng et al. 14 reported that ADP-induced platelet aggregation was inhibited by citalopram, but not ADP-induced Ca 2+ signalling. Notably, Ca 2+ -dependent Rap1 activation in both platelets and neutrophils is mediated by CalDAG-GEFI 15, 21 . Our results from an in vitro fluorescence-based binding assay show citalopram inhibits CalDAG-GEFI-mediated nucleotide exchange of Rap1B. The recovery of CRPXL-, collagen-and U46619-induced aggregation after washing out citalopram (Fig. 5, Supplementary Figs S4 and S5) indicates that this inhibition by citalopram is reversible. We therefore propose that citalopram binds directly and reversibly to either CalDAG-GEFI, Rap1 or a complex of both, thereby inhibiting Rap1 activation.
Comparatively few studies have reported the in vitro effects of SSRIs on neutrophils. Although fluoxetine has previously been shown to inhibit some neutrophil functions 22 , we believe that ours is the first report of citalopram inhibiting human neutrophil function. Unlike platelets, neutrophils do not express SERT 32 . Therefore, our results provide further confirmation of a direct and SERT-independent mechanism of action of citalopram in neutrophils and, by extension, platelets.
We have previously reported that citalopram inhibited collagen-induced aggregation and phosphorylation of molecules in the GPVI signalling pathway 10 . We now report that citalopram also inhibits platelet aggregation induced by CRPXL, a GPVI-selective agonist, and reduces the binding of anti-GPVI antibodies to unstimulated platelets. One possible explanation for these results is a reduction in surface receptor number, either by shedding or internalisation. However, for a full agonist, a reduction in receptor number is predicted to reduce the observed potency of the agonist 33 , and this has previously been demonstrated for CRPXL-induced aggregation in platelets with 50% levels of GPVI 34 . Thus, the similarity in CRPXL responsiveness of untreated resuspended platelets (Fig. 5f, condition (3) ) and citalopram-pre-treated resuspended platelets (Fig. 5f, condition (4) ) suggests that little if any GPVI was lost from the platelet surface as a result of citalopram treatment. Moreover, our data show that inhibition of CRPXL-induced platelet aggregation by citalopram is both instantaneous in onset and fully reversible. Taken together, these data strongly support a reversible, competitive mechanism of action for citalopram, rather than a reduction in surface receptor expression. We therefore propose that citalopram binds directly to GPVI-FcRγ chain complex, thereby preventing collagen-and CRPXL-induced platelet activation.
Our proposal that citalopram exerts two distinct mechanisms of action is further supported by the observed inhibitory potencies of citalopram in our studies. The Schild analysis indicates that citalopram binds to GPVI/FcRγ chain with a K d of approximately 16 µM. This is wholly consistent with data reported in our previous study 10 showing that 20 µM citalopram caused an approximate 2-fold rightward shift of the collagen concentration-response curve but had no discernible effect on U46619-induced aggregation. pIC 50 values for inhibition of GPVI-independent functions: aggregation induced by U46619 (4.15 ± 0.27) and ionomycin (3.98 ± 0.09); PAF-induced activation of neutrophil α M β 2 (4.02 ± 0.15); adhesion of platelets (4.00 ± 0.07) and neutrophils (3.88 ± 0.04) to fibrinogen; and CalDAG-GEFI-dependent Rap1B activation (3.67 ± 0.32), are all consistent with citalopram binding to and inhibiting CalDAG-GEFI/Rap1B at a concentration of approximately 100 µM. This is further reflected by the Schild analysis showing a rightward shift in the CRPXL concentration-response curves consistent with competitive antagonism at citalopram concentrations up to 50 µM, whereas at higher concentrations the shift was greater (Fig. 6) caused by the combination of the two distinct inhibitory mechanisms outlined above.
Citalopram may inhibit platelets and neutrophils through other unidentified mechanisms that are distinct from SERT blockade. For example, Bonnin et al., (2012) 35 have proposed that (R)-citalopram, the lower potency isomer 36 , may act via the orphan sigma-1 receptor. However, as we have previously noted, this is unlikely to be the mechanism responsible for the action of citalopram in platelets 10 . In summary, we propose a model (Fig. 7) in which citalopram binds to two distinct molecular targets: (1) GPVI/FcRγ chain (K d ≈ 16 µM) and (2) CalDAG-GEFI/Rap1B (K d ≈ 100 µM). This model predicts that citalopram would selectively disrupt GPVI-dependent platelet activation at concentrations between 20 and 50 µM, and above 50 µM, it would also inhibit Ca 2+ -dependent functions mediated through CalDAG-GEFI. These two novel, putative and distinct inhibitory mechanisms of action: (1) competitive antagonism of GPVI-FcRγ chain inhibition and (2), inhibition of CalDAG-GEFI-mediated nucleotide exchange of Rap1B, both need much higher concentrations of citalopram than are required to inhibit SERT, its primary mechanism of action. Hence, these effects are unlikely to be of clinical significance 10 , either as a cause of reported bleeding complications [37] [38] [39] [40] [41] , or as a strategy for reducing cardiovascular disease. Further studies will be required to confirm these putative mechanisms. However, if confirmed, citalopram may prove to be a useful investigative tool for the study of CalDAG-GEFI, Rap1, and GPVI signalling, as well as a practical chemical starting point for the discovery of more selective and potent inhibitors. A potent, selective GPVI antagonist could be a potentially useful anti-thrombotic agent and inhibitors of CalDAG-GEFI/Rap1 may have a wide range of uses in haematopoietic cells. and the resulting platelet pellet resuspended in a modified calcium-free Tyrode's buffer (CFT; 137 mM NaCl, 11.9 mM NaHCO 3 , 0.4 mM NaH 2 PO 4 , 2.7 mM KCl, 1.1 mM MgCl 2 , 5.6 mM glucose; pH = 7.4). Platelet counts were adjusted to 2 × 10 8 mL −1 using a Z2 Coulter particle counter (Beckman Coulter, High Wycombe, U.K.).
Neutrophil preparation. Citrated blood was mixed 2:1 with a saline solution of dextran-500 (final concentration of 1% [w/v]) and left for 30 min to allow red blood cell (RBC) sedimentation, whilst retaining white blood cells (WBCs) within the PRP. WBC-rich PRP was aspirated and layered over a discontinuous density gradient of Percoll ® (1.5 mL of 1.088 g mL −1 Percoll ® , carefully layered on top of 1.5 mL of 1.100 g mL −1 Percoll ® ). Samples were centrifuged (600 × g, 20 min) to separate granulocytes from the lower-density platelets, lymphocytes and monocytes. The isolated granulocyte band was aspirated, washed with phosphate-buffered saline (PBS), centrifuged (300 × g, 5 min) and resuspended in CFT. The cell concentration was adjusted to 1 × 10 6 mL −1 using a Z2 Coulter particle counter (Beckman Coulter, High Wycombe, U.K.).
Platelet aggregometry. Platelet aggregation was measured by turbidimetric aggregometry as previously described 10, 42 using two Aggregation Remote Analyzer Modules (AggRAM) with HemoRAM software (v1.2) (Helena Biosciences, Newcastle, U.K.). Washed platelets (WP) (247.5 µL, 2 × 10 8 mL −1 ) were aliquoted into glass cuvettes containing magnetic stir bars. 2.5 µL agonist was added and aggregation recorded at 37 °C with a stir speed of 1,000 rpm. The maximum extent of aggregation over 6 min was determined as previously described 43 .
Monitoring cytosolic calcium concentration. Changes in the cytosolic concentration of Ca 2+ ([Ca 2+ ] cyt ) were monitored using the fluorescent Ca 2+ indicator, Fura-2. PRP or isolated neutrophils were incubated for 30 min at 37 °C with 2.5 µM Fura-2 AM. With PRP, WP preparation was subsequently continued as described above. Fura-2-loaded neutrophils were centrifuged (300 × g, 5 min) and resuspended in fresh CFT to 1 × 10 6 mL −1 . Fura-2 fluorescence was measured using a Cairn Optoscan Spectrophotometer and Acquisition Engine (v1. For active Rap1 (i.e., Rap1-GTP) quantification, the remaining 480 µL sample was aliquoted into filter spin cups containing 100 µL of 50% glutathione-agarose beads and 20 µg of GST-RalGDS-RBD fusion protein. Samples were briefly vortexed then incubated with gentle rocking (1 hour, 4 °C). Samples were centrifuged (8,000 × g, 1 min) and washed 3 times with 400 µL LBW, before the addition of 50 µL Laemmli buffer. Samples were then centrifuged (8,000 × g, 2 min) through the spin cups to obtain bead-free samples for Western blot analysis.
Total Rap1 and Rap1-GTP samples underwent SDS PAGE and Western blot analysis. Samples were added to 10 well 4-12% pre-cast NuPage Bis-Tris gels (Invitrogen, Paisley, U.K.), followed by SDS/PAGE separation and transfer to PVDF membranes (Millipore, Watford, U.K.). Membranes were incubated with Rap1 primary antibodies (Thermo Fisher Scientific, Loughborough, U.K) followed by incubation with HRP-conjugated secondary antibodies (Dako, Ely, U.K.). Enhanced chemiluminescence (ECL) and X-ray hyperfilm ® (Amersham Biosciences, Buckinghamshire, U.K.) were used to detect protein bands. Developed X-ray films were scanned, and unprocessed images analysed using ImageJ (v1.50) as follows: identical areas (height (100) × width (150) = 15,000 pixels) were drawn around each protein band and the density of all pixels (scale 0-255 each) summed. The density of each area was therefore quantified on a scale from 0 (totally white) to 3,825,000 (totally black). Values are presented as % black. Uncropped images of X-ray films used for quantification of Rap1-GTP are shown in Supplementary Figs S7 and S8.
Monitoring Rap1 nucleotide exchange activity. The rate of Rap1 nucleotide exchange was measured using a fluorescence-based in vitro enzyme assay 17, 45, 46 . 100 µL of reaction buffer (20 mM Tris base, 150 mM NaCl, 5 mM MgCl 2 , 2 mM dithiothreitol, 10% [v/v] glycerol, 0.08% [v/v] NP-40, 1 µM Rap1B, 0.1 µM BODIPY-FL-GDP, pH = 7.5) was aliquoted into wells of a Nunc F96 well, black, flat-bottomed plate and the baseline fluorescence intensity (F.I.) recorded (excitation 485 nm; emission 520 nm) for 3 min with a Fluostar Optima plate reader (BMG Labtech, Aylesbury, U.K.). Measurements were halted and CalDAG-GEFI (0.3 µM) added to increase the rate of BODIPY-FL-GDP exchange onto Rap1, thereby increasing F.I. Recording was resumed and the average F.I. prior to CalDAG-GEFI addition subtracted from the final F.I. 20 min after the addition of CalDAG-GEFI (ΔF.I.).
Rap1B and CalDAG-GEFI were cloned from human genes into a protein expression vector p15LIC2 6xHis, which was purified in E. coli, as previously described 17 . Both proteins contained a C-terminal truncation (p.(Lys168_Leu184del) and p.(Ala552_Leu609del), respectively) which removed disordered regions to improve stability during the purification process, while leaving all the functional domains intact. Protein sequences (native and recombinant mutants) for both Rap1B and CalDAG-GEFI are shown in Supplementary Fig. S9 . (CD11b). Neutrophils (100 µL, 1 × 10 6 mL −1 ) were incubated with the active CD11b antibody in the absence of light (5 min, 4 °C). Samples were fixed with 2% [v/v] paraformaldehyde and neutrophils gated by forward scatter (FSC), side scatter (SSC) and CD15 + criteria. The median fluorescence intensity (M.F.I.) of activated CD11b from 30,000 gated events was then determined for each sample using an Accuri TM C6 flow cytometer (BD Bioscience, Oxford, U.K.).
Neutrophil integrin
Neutrophil adhesion. The adhesion of neutrophils to fibrinogen under static conditions was quantified by adapting a protocol developed to measure levels of cell-derived acid phosphatase (EC 3.1.3.2) 47 . Immulon-2HB 96 flat-bottom well plates (Thermo Fisher Scientific, Loughborough, U.K.) were incubated overnight at 4 °C with 100 μL of fibrinogen (10 μg mL −1 in saline). Excess ligand was discarded, and wells blocked with 175 μL BSA (5% [w/v] in CFT) for 1 hour. Wells were washed three times with BSA (0.1% [w/v] in CFT). 50 μL of isolated neutrophils (4.00 × 10 6 mL −1 ) were added to wells and left for 1 hour at room temperature. Samples were discarded, and the wells washed as before, followed by the addition of 150 μL of citrate lysis buffer (3.53 mM pNPP, 71.4 mM trisodium citrate, 28.55 mM citric acid, 0.1% [v/v] Triton X-100; pH 5.4). After 1 hour, 100 μL of 2 M NaOH was added and absorbance measured at 405 nm with a Sunrise TM plate reader (Tecan, Reading, U.K.).
Lactate dehydrogenase cytotoxicity assay. LDH release from neutrophils was measured to determine drug-induced cytotoxicity and cytolysis, using a Pierce LDH Activity Assay Kit (Thermo Fisher Scientific, Loughborough, U.K.). Neutrophils (250 µL, 1 × 10 6 mL −1
) were centrifuged (8,000 × g, 1 min) and 50 µL of supernatant was aliquoted into wells of an Immulon-2HB 96-well flat-bottom plate. 50 µL of the proprietary reaction mixture (Thermo Fisher, product code: 1862887) was added to each well for 30 min. 50 µL of the proprietary stop solution (Thermo Fisher, product code: 1862880) terminated the reaction and background absorbance at 680 nm was subtracted from the absorbance at 490 nm. Measurements were made using a Sunrise TM plate reader (Tecan, Reading, U.K.).
Antibody Binding to Glycoprotein VI. The binding of antibodies to dimeric or total (dimeric and monomeric) platelet GPVI was quantified as previously described using 204-11 Fab 48 and HY-101 49 antibodies, respectively. WP (2.50 × 10 7 mL −1 ) were incubated for 10 min with either HY-101 (5 µg mL −1 ) or 204-11 Fab (10 µg mL −1 ). Murine IgG 2a κ or Fab were used as corresponding isotype controls, respectively. 5 µg mL −1 of Alexa488-conjugated anti-mouse F(ab) 2 was subsequently added and incubated in the dark for 10 min. Samples were diluted 1:8 in CFT and the M.F.I. measured using an Accuri TM C6 flow cytometer (BD Bioscience, Oxford, U.K.).
Data and statistical analysis. Concentration-response data were modelled using a four-parameter logistic (4PL) model 
